An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Saphnelo

Chemical Nameanifrolumab-fnia
Dosage FormInjection (intravenous; 150 mg/mL)
Drug ClassReceptor antagonists
SystemImmune
CompanyAstraZeneca
Approval Year2021

Indication

  • For the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy.
Last updated on 11/30/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Saphnelo (anifrolumab-fnia) Prescribing Information2021AstraZeneca Pharmaceuticals LP, Wilmington, DE
Document TitleYearSource
Biologics targeting type I interferons in SLE: A meta-analysis and systematic review of randomised controlled trials.2020Lupus
Additional improvements in clinical response from adjuvant biologic response modifiers in adults with moderate to severe systemic lupus erythematosus despite immunosuppressive agents: A systematic review and meta-analysis.2017Clinical Therapeutics